Skip to content
Buy This GLP
← Research
Evidence

Tirzepatide Hitting Weight, Blood Pressure and Cholesterol Targets at Once

A post hoc SURMOUNT analysis found that 22–34% of tirzepatide participants met weight, blood pressure and cholesterol thresholds together at the 15% weight-loss cutoff.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Hit all three targetstirzepatideplacebo at start≥5% weight + BP + lipids32–38%2–8%≥10% weight + BP + lipids28–37%1–5%≥15% weight + BP + lipids22–34%1–3%Placebo column excludes the withdrawal group.

Tirzepatide participants were more likely than placebo participants to meet a combined weight, blood pressure and cholesterol target in an exploratory analysis of four SURMOUNT trials. The analysis counted how often the same person reached all three thresholds [1].

How the targets were measured

The weight-loss tool focuses on changes in body weight. This analysis also required a change in systolic blood pressure and a specific non-HDL cholesterol level. Researchers evaluated each trial separately at week 72 in SURMOUNT-1 through -3 and week 88 in SURMOUNT-4 [1].

Eli Lilly funded the analysis. It used on-treatment data from participants with baseline and at least one follow-up measurement for each measure. The authors estimated missing endpoint measurements from available data. Treatment comparisons had P < .001 without adjustment for multiple comparisons[1].

How many participants reached all three

With a weight-loss threshold of at least 5%, the paper’s reported ranges were 32–38% with tirzepatide and 2–8% with placebo. At the 10% threshold the ranges were 28–37% and 1–5%, and at the 15% threshold they were 22–34% and 1–3%. The placebo ranges refer to groups that started on placebo [1].

SURMOUNT-4 used a withdrawal design. Everyone received tirzepatide for 36 weeks before randomization to continue it or switch to placebo. Of those who switched, 14%, 10% and 8% met all three criteria using the 5%, 10% and 15% weight-loss thresholds, respectively [1].

What the study tells us about heart outcomes

The guide to tirzepatide’s cardiovascular evidence covers trials that measured clinical events. The SURMOUNT analysis counted risk markers. In the separate SURPASS-CVOT trial of adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide for cardiovascular death, heart attack or stroke[2].

Frequently asked

What did the three-part target measure?
Participants needed to meet a weight-loss threshold, lower their systolic blood pressure by at least 5 mmHg, and finish with non-HDL cholesterol below 130 mg/dL.
Why is the SURMOUNT-4 placebo group different?
Those participants received tirzepatide for 36 weeks before switching to placebo, unlike groups assigned to placebo from the start.
Did this analysis measure heart attacks or strokes?
It measured weight, blood pressure and non-HDL cholesterol. Separate trials, including SURPASS-CVOT in adults with type 2 diabetes and atherosclerotic cardiovascular disease, measured actual cardiovascular events.

Sources

  1. [1] Sattar N, et al. (2026). Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials PLOS ONE. PMID 42594122
  2. [2] Nicholls SJ, et al. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes New England Journal of Medicine. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence